Stock Events

Stock Events

Novo Nordisk

R$97.79

5203

+R$1.53+1.59% Friday 20:05

Statistics

Day High

97.79

Day Low

96.89

52W High

103.1

52W Low

45.59

Volume

4,371

Avg. Volume

7,274

Mkt Cap

1.58T

P/E Ratio

5.06

Dividend Yield

0.98%

Dividend

0.95

Upcoming

Dividends

0.98%Dividend Yield

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

-1.7%

1Y Growth

-25.35%

Earnings

2MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

0

2.93

5.85

8.78

Expected EPS

N/A

Actual EPS

5.68

People Also Follow

This list is based on the watchlists of people on Stock Events who follow N1VO34.SA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Sanofi competes directly with Novo Nordisk in the diabetes and insulin markets, offering similar products and therapies.

Eli Lilly is a major competitor in the diabetes care market, particularly in insulin and GLP-1 receptor agonists, directly competing with Novo Nordisk's portfolio.

AstraZeneca competes in the diabetes sector with its range of type 2 diabetes medications, posing competition to Novo Nordisk's diabetes care products.

Merck is a competitor in the diabetes market with its drug Januvia among others, competing with Novo Nordisk's diabetes management products.

Bristol-Myers Squibb

Bristol Myers Squibb competes in the area of diabetes and cardiovascular diseases, areas where Novo Nordisk also has a significant presence.

Pfizer competes with Novo Nordisk in various therapeutic areas, including chronic diseases, though not as directly in diabetes.

Novartis competes across a broad range of therapeutic areas including cardiovascular, which overlaps with Novo Nordisk's interests.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division Janssen, competes in several areas including diabetes care.

Abbott Laboratories

Abbott Laboratories competes with Novo Nordisk in the broader healthcare market, including diabetes management through its glucose monitoring devices.

Thermo Fisher Scientific

Thermo Fisher Scientific competes indirectly by providing instruments and reagents for diabetes research, affecting the market landscape.

About

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Show more...

CEO

Mr. Lars Fruergaard Jorgensen

Employees

52696

Country

Denmark

ISIN

BRN1VOBDR005

Listings